The shape-shifting telehealth company has spent the past year trying to cash in on GLP-1s, the hottest drug to hit weight loss in decades. It could all slip away. By Madison Muller and Devin Leonard

How a Die-Hard Libertarian Is Negotiating Lower Health-Care Costs
22:36

James Patterson’s Authorship Operation Welcomes Viola Davis and MrBeast
38:15

The Caribbean Nation Unexpectedly Going Along With Trump’s Drug-Boat Narrative
13:32